Survival and severe neonatal morbidity at discharge according to antihypotensive treatment
| No. of events/total (%) | ||||||
|---|---|---|---|---|---|---|
| Overall cohort* | Matched cohort | |||||
| Untreated | Treated | p Value† | Untreated | Treated | p Value‡ | |
| Survival without severe morbidity at discharge§ | 170/325 (54.7) | 78/131 (61.3) | 0.20 | 58/119 (48.7) | 73/119 (61.3) | 0.049 |
| Survival at discharge | 262/325 (82.2) | 107/131 (82.2) | 0.99 | 92/119 (77.3) | 99/119 (83.2) | 0.29 |
| Severe cerebral lesion | 58/321 (16.9) | 15/131 (10.9) | 0.10 | 31/117 (26.5) | 12/119 (10.1) | 0.002 |
| Grade III IVH or IPH | 49/321 (14.1) | 14/131 (10.0) | 0.23 | 26/117 (22.2) | 12/119 (10.1) | 0.015 |
| Necrotising enterocolitis | 16/321 (4.8) | 4/130 (3.5) | 0.58 | 6/118 (5.1) | 4/119 (3.4) | 0.52 |
| Among survivors | ||||||
| Severe bronchopulmonary dysplasia (BPD) | 61/259 (22.6) | 21/107 (18.0) | 0.32 | 20/91 (22.0) | 19/99 (19.2) | 0.64 |
| Severe retinopathy of prematurity | 10/262 (3.5) | 1/107 (0.8) | 0.12 | 2/92 (2.2) | 1/99 (1.0) | 0.53 |
Denominators vary according to the number of missing data items for each variable.
*% and p values are weighted to take into account differences in the sampling process between gestational age groups.
†χ2 test.
‡Generalised estimating equations to account for paired data.
§Severe morbidity was defined as severe BPD, severe necrotising enterocolitis or any of the following severe cerebral abnormalities on cranial ultrasonography: intraventricular haemorrhage with ventricular dilatation (grade III IVH) or intraparenchymal haemorrhage (IPH) or cystic periventricular leukomalacia (see detailed definitions in the text).